Possible side effects

Kelsey is not taking COBENFY. Kelsey and Jia have been compensated for their time.

Most common side effects

These were experienced by at least 5% of patients taking COBENFY.

Adverse reaction COBENFY
(n=251)
Sugar pill
(n=253)
Nausea 19% 4%
Stomach upset or burning
(dyspepsia)
18% 5%
Constipation 17% 7%
Vomiting 15% 1%
High blood pressure 11% 2%
Stomach (abdominal) pain 8% 4%
Diarrhea 6% 2%
Increased heart rate 5% 2%
Dizziness 5% 2%
Heartburn (gastrointestinal
reflux disease)
5% <1%

These are not all of the possible side effects of COBENFY. Your healthcare provider may lower your dose or stop treatment with COBENFY if you get certain side effects.

COBENFY may cause serious side effects, including:

Problems with emptying your bladder (urinary retention), risks in people with liver problems, risks in people with bile duct and gallbladder problems (biliary disease), slow emptying of your stomach (decreased gastrointestinal motility), serious allergic reactions (angioedema), an eye problem called narrow-angle glaucoma, increases in heart rate, side effects in people with kidney problems, and central nervous system problems.

Get information on taking COBENFY

Explore dosing options and how to take COBENFY.

Bryan is taking COBENFY. Bryan was compensated for his time.

First instance of nausea and vomiting often occurred during the first 2 weeks of treatment and generally decreased over time

Chart displaying initial onset of nausea generally decreases over time while taking COBENFY (xanomeline and trospium chloride)
Chart displaying initial onset of vomiting generally decreases over time while taking COBENFY (xanomeline and trospium chloride)
Icon

If you experience nausea or vomiting, ask your healthcare provider about options that may help.

Weight changes over time

Infographic illustrating the effects on weight while taking COBENFY (xanomeline and trospium chloride)
* The results are from 1-year studies where participants and their physicians knew they were taking COBENFY, which may have influenced the results.
On average, patients lost 5.6 lbs in a year-long extension trial. 17.6% of patients had a decrease in body weight of ≥7%. 4.1% of patients had an increase in body weight of ≥7%.

COBENFY and uncontrolled movements
People taking COBENFY had similar rates of uncontrolled facial or body movements (2%) as those taking a sugar pill (<1%).

Sagan is taking COBENFY. Sagan was compensated for his time.



Cobenfy, Cobenfy Cares, and the Cobenfy logo are trademarks of Karuna Therapeutics, Inc., a Bristol Myers Squibb company.
© 2025 Bristol-Myers Squibb Company. 
1629-US-2500777 08/25
This website is intended for U.S. residents 18 years of age or older.